Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2

Russell M. Petrak, Nathan C. Skorodin, Nicholas W. Van Hise, Robert M. Fliegelman, Jonathan Pinsky, Vishal Didwania, Michael Anderson, Melina Diaz, Kairav Shah, Vishnu V. Chundi, David W. Hines, Brian P. Harting, Kamo Sidwha, Brian Yu, Paul Brune, Anjum Owaisi, David Beezhold, Joseph Kent, Dana Vais, Alice Han, Neethi Gowda, Nishi Sahgal, Jan Silverman, Jonathan Stake, Jenie Nepomuceno, Renuka Heddurshetti
doi: https://doi.org/10.1101/2020.06.05.20122622
Russell M. Petrak
1Metro Infectious Disease Consultants, Burr Ridge, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rpetrak@midcusa.com
Nathan C. Skorodin
1Metro Infectious Disease Consultants, Burr Ridge, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nskorodin@midcusa.com
Nicholas W. Van Hise
1Metro Infectious Disease Consultants, Burr Ridge, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert M. Fliegelman
1Metro Infectious Disease Consultants, Burr Ridge, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Pinsky
2Metro Infectious Disease Consultants, Naperville, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vishal Didwania
3Metro Infectious Disease Consultants, Elmhurst, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Anderson
4Metro Infectious Disease Consultants, Kankakee, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melina Diaz
5Metro Infectious Disease Consultants, Atlanta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kairav Shah
5Metro Infectious Disease Consultants, Atlanta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vishnu V. Chundi
6Metro Infectious Disease Consultants, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W. Hines
6Metro Infectious Disease Consultants, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian P. Harting
7Metro Infectious Disease Consultants, Downers Grove, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kamo Sidwha
6Metro Infectious Disease Consultants, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Yu
6Metro Infectious Disease Consultants, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Brune
8Metro Infectious Disease Consultants, Kansas City, Missouri
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anjum Owaisi
9Metro Infectious Disease Consultants, Bolingbrook, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Beezhold
3Metro Infectious Disease Consultants, Elmhurst, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Kent
10Metro Infectious Disease Consultants, Oak Lawn, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dana Vais
6Metro Infectious Disease Consultants, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice Han
6Metro Infectious Disease Consultants, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neethi Gowda
11Metro Infectious Disease Consultants, Troy, Michigan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nishi Sahgal
12Metro Infectious Disease Consultants, Hinsdale, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Silverman
13Metro Infectious Disease Consultants, Royal Oak, Michigan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Stake
14Metro Infectious Disease Consultants, Waukegan, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jenie Nepomuceno
15Metro Infectious Disease Consultants, McHenry, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renuka Heddurshetti
16Metro Infectious Disease Consultants, Detroit, Michigan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Tocilizumab is an IL-6 receptor antagonist with the ability to suppress the cytokine storm in critically ill patients infected with SARS-CoV-2.

Methods We evaluated patients treated with tocilizumab for a SARS-CoV-2 infection who were admitted between 3/13/20 and 4/16/20. This was a multi-center study with data collected by chart review both retrospectively and concurrently. Parameters evaluated included age, sex, race, use of mechanical ventilation (MV), usage of steroids and vasopressors, inflammatory markers, and comorbidities. Early dosing was defined as a tocilizumab dose administered prior to or within one (1) day of intubation. Late dosing was defined as a dose administered greater than one (1) day after intubation. In the absence of mechanical ventilation, the timing of the dose was related to the patient’s date of admission only.

Results We evaluated 145 patients. The average age was 58.1 years, 64% were male, 68.3% had comorbidities, and 60% received steroid therapy. Disposition of patients was 48.3% discharged and 29.3% expired, of which 43.9% were African American. Mechanical ventilation was required in 55.9%, of which 34.5% expired. Avoidance of MV (p value = 0.002) and increased survival (p value < 0.001) was statistically associated with early dosing.

Conclusions Tocilizumab therapy was effective at decreasing mortality and should be instituted early in the management of critically ill COVID-19 patients.

Summary Utilizing tocilizumab early in the treatment course of critically ill patients with COVID-19 resulted in significant decreases in mortality and the avoidance of mechanical ventilation.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding was received

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Western IRB considered this an exempt project

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Upon request, we will make a de-identified dataset available

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 08, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2
Russell M. Petrak, Nathan C. Skorodin, Nicholas W. Van Hise, Robert M. Fliegelman, Jonathan Pinsky, Vishal Didwania, Michael Anderson, Melina Diaz, Kairav Shah, Vishnu V. Chundi, David W. Hines, Brian P. Harting, Kamo Sidwha, Brian Yu, Paul Brune, Anjum Owaisi, David Beezhold, Joseph Kent, Dana Vais, Alice Han, Neethi Gowda, Nishi Sahgal, Jan Silverman, Jonathan Stake, Jenie Nepomuceno, Renuka Heddurshetti
medRxiv 2020.06.05.20122622; doi: https://doi.org/10.1101/2020.06.05.20122622
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2
Russell M. Petrak, Nathan C. Skorodin, Nicholas W. Van Hise, Robert M. Fliegelman, Jonathan Pinsky, Vishal Didwania, Michael Anderson, Melina Diaz, Kairav Shah, Vishnu V. Chundi, David W. Hines, Brian P. Harting, Kamo Sidwha, Brian Yu, Paul Brune, Anjum Owaisi, David Beezhold, Joseph Kent, Dana Vais, Alice Han, Neethi Gowda, Nishi Sahgal, Jan Silverman, Jonathan Stake, Jenie Nepomuceno, Renuka Heddurshetti
medRxiv 2020.06.05.20122622; doi: https://doi.org/10.1101/2020.06.05.20122622

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (51)
  • Cardiovascular Medicine (453)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (158)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5274)
  • Forensic Medicine (3)
  • Gastroenterology (197)
  • Genetic and Genomic Medicine (759)
  • Geriatric Medicine (80)
  • Health Economics (213)
  • Health Informatics (700)
  • Health Policy (361)
  • Health Systems and Quality Improvement (224)
  • Hematology (99)
  • HIV/AIDS (164)
  • Infectious Diseases (except HIV/AIDS) (5901)
  • Intensive Care and Critical Care Medicine (363)
  • Medical Education (105)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (769)
  • Nursing (43)
  • Nutrition (132)
  • Obstetrics and Gynecology (144)
  • Occupational and Environmental Health (234)
  • Oncology (481)
  • Ophthalmology (152)
  • Orthopedics (39)
  • Otolaryngology (95)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (99)
  • Psychiatry and Clinical Psychology (865)
  • Public and Global Health (2026)
  • Radiology and Imaging (350)
  • Rehabilitation Medicine and Physical Therapy (158)
  • Respiratory Medicine (287)
  • Rheumatology (94)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (77)
  • Surgery (110)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)